Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Most relevant news about MERCK & CO., INC.
09:16aMERCK : Goldman Sachs Adjusts Price Target for Merck to $104 From $102, Maintain..
MT
09:14aMERCK : SVB Leerink Adjusts Price Target on Merck & Company to $101 From $99, Ma..
MT
07/29SECTOR UPDATE : Health Care Stocks Closing Slightly Higher
MT
07/29SECTOR UPDATE : Health Care Stocks Inching Higher This Afternoon
MT
07/29MERCK : weighed down by charges in Q2, but drug sales rebound
AQ
07/29MERCK : Announces Appointment of Cristal N. Downing as Chief Communications & Pu..
BU
07/29Merck & Co., Inc. Announces Appointment of Cristal N. Downing as Chief Commun..
CI
07/29MERCK : Reports Higher Second-Quarter Results But Mixed Against Street Views, Na..
MT
07/29SECTOR UPDATE : Health Care Stocks Cautiously Up Ahead of Thursday's Opening Bel..
MT
07/29Today on Wall Street: GDP growth misses estimates
07/29MERCK : 2Q21 Merck Earnings Presentation
PU
07/29MERCK : 2Q21 Merck Other Financial Disclosures
PU
07/29MERCK : Posts Higher Q2 Earnings, Sales; Revises 2021 Outlook
MT
07/29MERCK : Q2 Earnings Snapshot
AQ
07/29MERCK : Earnings Flash (MRK) MERCK & CO. Reports Q2 EPS $1.31
MT
07/29MERCK : Earnings Flash (MRK) MERCK & CO. Posts Q2 Revenue $11.4B
MT
07/29GUIDANCE : (MRK) MERCK & CO. Forecasts Fiscal Year 2021 Revenue Range $46.4B - $..
MT
07/29GUIDANCE : (MRK) MERCK & CO. Sees Fiscal Year 2021 EPS Range $5.47 - $5.57
MT
07/29MERCK : Announces Second-Quarter 2021 Financial Results
BU
07/29Merck & Co., Inc. Provides Earnings Guidance for the Full Year of 2021
CI
07/28ALX ONCOLOGY : Starts Dosing in Mid-Stage Trial of Head, Neck Cancer Combo Thera..
MT
07/28MERCK : Announces Phase 3 KEYNOTE-355 Trial Met Primary Endpoint of Overall Surv..
AQ
07/28MERCK : FDA Approves KEYTRUDA for Treatment of Patients With High-Risk Early Sta..
AQ
07/28Today on Wall Street: Better-than-expected earnings ahead of the Fed
07/28ALX Oncology Announces First Patient Dosed in ASPEN-04, a Phase 2 Study of AL..
CI
07/28ANALYST RECOMMENDATIONS : Flutter, Hasbro, MGM Resort, Microsoft Vodafone...
07/27MERCK : Keeps Quarterly Dividend at $0.65 per Share, Payable Oct. 7 to Sharehold..
MT
07/27MERCK : Announces Fourth-Quarter 2021 Dividend
BU
07/27Merck & Co., Inc., Announces Fourth-Quarter 2021 Dividend, Payable on October..
CI
07/27MERCK : Truist Assumes Merck & Company at Buy Rating With $92 Price Target
MT
07/27MERCK : Wins US FDA Approval For Breast Cancer Drug
MT
07/27Merck Launches New Green Solvents for Photoresist Removal in Chip Production
CI
07/27MERCK : Announces Phase 3 KEYNOTE-355 Trial Met Primary Endpoint of Overall Surv..
BU
07/27Merck Announces Phase 3 Keynote-355 Trial Met Primary Endpoint of Overall Sur..
CI
07/27MERCK : FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of Patients With Hi..
BU
07/27Merck Announces U.S. Food and Drug Administration Has Approves Keytruda
CI
07/27Merck's Keytruda Hits Key Endpoint in Metastatic Triple-Negative Breast Cance..
DJ
07/27Merck Gets FDA Expanded OK for Keytruda in Breast Cancer
DJ
07/23MERCK : FDA Approves KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Combinat..
AQ
07/22ADAGENE : Agrees With Merck on Trials of Its Monoclonal Antibodies With Keytruda..
MT
07/22MERCK : Eisai Win US FDA Approval of Keytruda Plus Lenvima Combination for Certa..
MT
07/22MERCK : FDA Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combin..
BU
07/22FDA Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® Combination for Patients..
CI
07/21MERCK : Teams up with Noxxon to Evaluate NOX-A12 in Combination With Keytruda in..
MT
07/21NOXXON Pharma N.V. Enters Second Clinical Collaboration with Merck & Co., Inc..
CI
07/21BAYER : Heart Failure Treatment Wins EU Market Authorization
MT
07/21MERCK : Secures European Approval for Verquvo for Chronic Heart Failure
MT
07/21MERCK : VERQUVO® (vericiguat) Approved in the European Union
BU
07/21European Commission (Ec) Grants Marketing Authorization in the European Union..
CI
07/21Merck Says Verquvo Granted Marketing Authorization in European Union
DJ
07/20MERCK : Presents New Data from Ongoing Phase 2a Clinical Trial Evaluating the Sa..
BU
07/20Merck Presents New Data from Ongoing Phase 2a Clinical Trial Evaluating the S..
CI
07/20Merck Posts Positive Safety Data for Investigational HIV Drug
DJ
07/19Ligand Pharmaceuticals Shares Rise 7% After FDA Approves Vaxneuvance
DJ
07/19MERCK : Announces U.S. FDA Approval of VAXNEUVANCE (Pneumococcal 15-valent Conju..
AQ
07/19PORTAGE BIOTECH CEO INTERVIEW EXPLAI : Prtg)
AQ
07/19LIGAND PHARMACEUTICALS INCORPORATED : Secures FDA Approval for Vaxneuvance in Ad..
MT
07/19MERCK : Pneumonia Vaccine Gets FDA OK
MT
07/16MERCK : Announces U.S. FDA Approval of VAXNEUVANCE™ (Pneumococcal 15-valen..
BU
07/16Merck Announces U.S. FDA Approval of VAXNEUVANCE™ (Pneumococcal 15-Valent Con..
CI
07/16MERCK : KEYTRUDA (pembrolizumab) Plus Chemotherapy Before Surgery and Continued ..
AQ
07/15MERCK : Keytruda Plus Chemotherapy Shows Positive Trial Results in Breast Cancer
MT
07/15MERCK : KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued..
BU
07/15Merck Announces Positive Event-Free Survival Data from the Pivotal Neoadjuvan..
CI
07/15Merck Says Data Positive From Keytruda Breast Cancer Study
DJ
07/14MERCK : RBC Lifts Price Target on Merck to $80 From $75 Ahead of Q2 Results, Rei..
MT
07/13Claus Egstrand appointed new CEO of Enzymatica
AQ
07/12SECTOR UPDATE : Health Care Stocks Hanging Onto Slim Monday Advance
MT
07/12SECTOR UPDATE : Health Care Stocks Scratching Out Narrow Rise
MT
07/12MERCK : Announces Presentation of New Data from Broad HIV Program at IAS 2021
BU
07/12MERCK : Interim Results from Phase 2/3 Studies of Molnupiravir, an Investigation..
BU
07/12Merck and Ridgeback Biotherapeutics Announces the Presentation of Previously ..
CI
07/09President Biden's Competition Order to Crack Down on Antitrust Practices by B..
MT
07/09GALECTIN THERAPEUTICS : Reports Positive Data From Trial of Belapectin, Keytruda..
MT
07/09Oncosec Medical Incorporated Enters into Clinical Research Cooperation Agreem..
CI
1  2  3  4  5  6  7  8  9  10Next
Official Publications
05/25Dividends 
05/11Report 
05/06Report 
05/05SEC Filing 10Q-1 
04/29SEC Filing 8K 
04/291st quarter results 
Upcoming event on MERCK & CO., INC.